An intrasanguineous host-mediated assay was used to determine the pattern of mutagenesis induced by the carcinogen aflatoxin Bl in the lad gene of Escherichia coli recovered from rat liver. To investigate the influence of different types of metabolic activation, the mutation spectrum induced by AFB1 activated in vitro by a commercially prepared S9 microsomal fraction from Aroclor 1254-treated rats was also obtained. A total of 281 forward mutations affecting the N-terminal region of the lad gene were characterized by DNA sequencing analysis. AFB1 induced similar type of mutations with similar site specificity when activated by the standard S9 fraction or by employing a rat host-mediated assay. These results indicate the ability of the in vitro S9 fraction to mimic the in vivo metabolism, suggesting that the same active metabolite, presumably AFB1 8,9-epoxide, is responsible for generating a similar pattern of DNA damage, as reflected in the similarity of mutational spectra. For both activation systems, most mutations (>90%) were base substitutions that occurred primarily at G:C pairs. Somewhat over one-half of G:C targeted substitutions were GC>TA transversions, other mutations being evenly divided between G:C>AT transitions and GOCG transversions. The mutational specificity exhibited by activated AFB1 can be explained by incorporation of different bases opposite a single type of non-instructive lesion during error-prone DNA synthesis. To what extent the mutations are due to the main adduct (AFB1-N7-Gua), its imidazolering-opened derivative or an apurinic site remains unknown.
Introduction
Epidemiological evidence correlates aflatoxin consumption with human liver cancer (1). Aflatoxin Bl (AFB1*) is the most abundant and the most carcinogenic of all naturally occurring aflatoxins. The AFB1 parent compound is not harmful prior to mammalian metabolic activation to form a highly reactive AFB1-8,9-epoxide (referred to as 2,3-epoxide in some publications) (2) . Cytochrome P450 is the principal enzyme system involved in the oxidative bioactivation of AFB1. Many isoforms of P450 are able to biotransform AFB1 to DNA-binding/mutagenic species (3) . Metabolically activated AFB1 reacts with DNA giving the chemically unstable 8,9-dihydro-8-(N 7 -guanyl)-9-hydroxyaflatoxin Bl adduct (AFB1-N7-Gua) (4) , which, in secondary reactions, either forms apurinic sites or ring opens to a stable derivative referred to © Oxford University Press as AFBl-triamino-Py or FAPYR (5) . Alternatively, the AFB1-8,9-epoxide can be rendered innocuous via phase II detoxification, in which glutathione 5-transferase conjugates the epoxide to glutathione and microsomal epoxide hydrolase converts the epoxide into AFBl-dihydrodiol (6) . Individuals with mutant genotypes at epoxide hydrolase and glutathione 5-transferase are at greater risk of developing hepatocellular carcinoma when exposed to AFB 1 (7) .
The metabolic activation system most commonly used in prokaryotic studies and other in vitro short-term mutagenicity tests, is the 9000 g supernatant (S-9) fraction of liver from rats pretreated with the enzyme inducer Aroclor 1254 (8) . The ability of induced S9 fraction to portray in vivo metabolism is a matter of concern. Reasons for in vitro and in vivo discrepancies are possibly associated with the use of subcellular fractions that do not mimic the entire metabolic competency of the intact mammalian cells, and with changing the balance between activation and detoxification reactions. Various in vivo mammalian activation systems have been developed to compensate for the limitations imposed by the use of tissue fractions to metabolize carcinogens/mutagens in vitro. These systems utilize the metabolic competency of the intact mammalian organism, but score for genotoxic effects in vitro following isolation of the affected target cells (8) . The hostmediated assay (HMA) combines in vivo metabolism with the power of genetic microbial systems. In the HMA, the chemical to be tested is activated in vivo and metabolites reach the indicator bacteria which are introduced into living animals and subsequently recovered and assayed for induced genetic effects (9) .
Mutational spectra achieved through the direct analysis of DNA sequence alterations provide valuable information in understanding the role of different premutagenic DNA lesions and neighbouring DNA sequences in the mutational process. A number of previous studies have investigated the mutagenic spectrum induced by AFB1 DNA lesions. In most of these studies, naked DNA was adducted in vitro with (i) AFB 1-2,3-dichloride, a synthetic model for the reactive metabolite (10), (ii) chemically synthesized AFBl-8,9-epoxide (11), or (iii) AFB1 activated by 3-methylcholanthrene-induced hamster liver S9 fractions (12) or by Aroclor-induced rat liver microsome (13) . Modified DNA was then used to transfect either bacteria (10,12) or human cells (11, 13) . Forward mutations in the lacZ a-complementing gene sequence (10,12) or in the Escherichia coli supF gene (11, 13) were identified and defined by DNA sequencing. Alternatively to in vitro modification of DNA, one study reported the frequency and type of supF mutations caused by the bioactivation of AFB1 within human cells transiently expressing rat liver cytochrome P4501A2 cDNA (14) . Likewise, another study analysed the types of AFB 1-induced base substitutions leading to specific amber and ochre nonsense mutations in the entire lad gene of Escherichia coli, after co-incubation of the bacteria with the mutagen in the presence of Aroclor-induced rat liver microsome (15) . The N-terminal region of the lacl gene which encodes the operator-binding domain of the repressor has proven to be a useful target for the molecular analysis of dominant lacl forward mutations (lacr d ) in E.coli cells. This target is highly responsive to amino acid substitutions and is large enough to reveal many frameshift, deletion and duplication mutations (16, 17) . The purpose of this study was to delineate in a comprehensive manner the nature of lacl~d forward mutations induced by AFB1 in E.coli recovered from the liver of treated rats (intrasanguineous host-mediated assay). To further examine the impact of metabolic activation in mutagenesis under physiological conditions, we have determined also the AFB1 mutational specificity under conditions in which the bacteria were exposed to AFB 1 activated in vitro by S9 fraction from Aroclor 1254-treated rats.
Materials and methods

Bacterial strain and media
The mutagenesis enhancing plasmid pKMlOl was transferred by conjugation to UC8310 [F~ araD8l arg56 nadll3 A(uvrB-Wo) A(pro-lacWlac-pro] (18). The resulting E.coli K-12 strain, named UC998, was used in the present study. Media were according to Miller (19) and Davis et al. (20) .
AFB1 in vitro treatment (S9 microsomal fraction)
Bacterial cells were grown at 37°C for 12 h with shaking (90 r.p.m.) in LuriaBertani (LB) nutrient medium. Cells were then harvested by centrifugation and resuspended in 0.2 M phosphate buffer, pH 7.4. An aliquot of 100 (Xl of bacterial suspension (containing around 1X10 8 cells), 500 nl of S9 mixture and 30 nl of the mutagen (AFB1 from Sigma) was pre-incubated at 37°C for 60 min with shaking (90 r.p.m.) in a total volume of 1 ml of phosphate buffer. After pre-incubation, 0.1 ml of the treated bacteria was combined in 2 ml of molten top agar and then poured on selective and non-selective plates for mutant and survivor counts, respectively. Liver S9 fractions from Aroclor 1254-induced male rat (Sprague-Dawley) were obtained from Iffa Credo, Lyon, France. The S9 mixture was prepared prior to each experiment and maintained at 0-4°C. The S9 mixture contained 5 mM glucose-6-phosphate, 4 mM NADP, 8 mM MgCl 2 , 33 mM KC1, 100 mM sodium phosphate buffer (pH 7.4) and 50 |il of the S9 fraction in 0.5 ml total volume. Mutants for mutational spectra were collected from 15 independent AFB1 treatments.
AFBI in vivo treatment (intrasanguineous host-mediated assay)
Bacterial cells were harvested from an overnight culture and resuspended in phosphate buffered saline (PBS) at a density of 2X10 10 cells/ml. AJiquots of 1 ml of bacteria suspension were injected into the lateral tail vein of nine vasodilated Wistar male rats (Mollegaard Breeding & Research Center Ltd, Skensved, Denmark) weighing approximately 160 g each. Fifteen minutes later the rats were intraperitoneally injected with 1 or 10 mg AFBl/kg body weight in DMSOxom oil 1:4. Control rats received only DMSOxom oil 1.4. After a 2-h incubation period, the rats were anaesthetized with carbon dioxide/ air. The livers were removed, washed twice in 0.15 M KC1, placed in 5 ml PBS and homogenized (Ultra-turrax mixer). Bacteria were then separated from the unbroken cells and debns by centrifugation for 10 min at 200 g. The supernatant was centrifuged twice for 10 min at 9000 g to pellet the bacteria. The pellet was then washed twice and resuspended in PBS. Dilutions of this homogenate were plated on selective and non-selective plates for mutant and survivor counts, respectively.
Selection and sequencing of lad' 11 mutations
Plates containing 750 mg/1 of phenyl-fJ-D-galactoside (Pgal, from Sigma) as the sole carbon source were used for selection of mutants that synthesize fj-galactosidase constitutively {lad~ or lacCf). Mutations occurring within the initial part of the lad gene were then isolated following a simple merodiploid complementation test (21) . The lad gene was amplified from colonies in a DNA thermal cycler (Perkin-Elmer Cetus) by using a Gene Amp Kit (Perkin-Elmer Cetus) and two specific 25-mer primers (supplied by Operon Technologies, INC) with their 3' ends at positions -16 and 1186, respectively. The PCR mixture was subjected to 30 cycles of heat treatment at 94, 55 and 72°C for 1, 1 and 3 mm (2" extension), respectively, and 72°C for 10 mm. PCR products were sequenced by using the Applied Biosystem (ABI model 373A) Taq DyeDeoxy™ Terminator Cycle Sequencing procedure following the manufacturer's specifications. The synthetic oligonucleotide 3'-AGTTGACCCACGGTCGCACC-5' was used as sequencing primer for the first 300 bp of the lacl gene.
Results
In this paper we describe the spectra of forward mutational changes observed in the /V-terminal region of the lacl gene of Eschenchia coli after AFBI treatment, where metabolic activation was carried out either by the intrasanguineous hostmediated assay (in vivo treatment) or by using the standard S9-liver fraction from Aroclor 1254-induced rats (in vitro treatment). The mutation spectra were obtained in bacterial strain UC998, a uvrB~ mutant that carries the mutagenesisenhancing plasmid pKMlOl, because it is well established that nucleotide excision repair plays a major role in the repair of DNA damage caused by AFBI, and that mutagenicity by AFBI is highly dependent on muc + loci mutagenic processing (15, 22) .
Lac constitutive mutations occurred in vitro at a frequency of 1545 X 10~6, which was 28.1-fold more than the mutation frequency of the untreated controls exposed to S9 mixture and to the mutagen solvent, but not to AFBI (Table I) . Of the constitutive induced mutants, 31% carried dominant mutations in the lacl gene, whereas only 13% of the spontaneous mutants resulted from dominant mutations in this gene. Thus, 2.5 |iM Treatment   42  56  57  75  92  93  95  104  120  140  174  181  182  185  186  191  201   ACG  CGC  GCA  TCT  CCG  CGC  CGT  CCA  TCT  AGT  CCC  GCG  CGT  GGC  GCA  ACA  GGC   49  53  57  59  75  80  84  86  92  93  116  120  134  143  150  158  160  169  174  178  185  186  198  201  210   49  56  92  93  132  146  149  155  178  185  186  197   ACG  TGT  GCA  AGA  TCT  TCA  ACC  CGT  CCG  CGC  CGT  TCT  GGA  GGA  GCG  GGA  AGC  ACA  CCC  ACC  GGC  GCA  GCG  GGC  TCG   ACG  CGC  CCG  CGC  CGG  AGC  GGC  GGC  ACC  GGC GCA GGC
In vitro
(S9 mix) 3 6 3 1 1 5 0 0 1 0 1 0 0 1 0 1 0 23 2 0 2 1 3 1 1 4 12 4 3 0 4 0 4 2 0 1 3 I 1 5 11 0 4 69 0 1 0 1 0 1 6 5 1 3 1 2
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In vivo (HMA) Subtotal   41  48  54  81  89  101  125  168  177   64  81  87  96  102  105  127  141  167  183  195   77  117  128  168  177  195   AAC  TAC  GTC  CAG  TTC  GAA  GAA  TAC  AAC   ATG  CAG  GTT  GTG  AAC  CAG  AAA  GTG  TTA  GTG  CTG   TTA  GTT  AAC  TAC AFBl generated a 68.1-fold increase in lad d mutations compared with the level observed in the untreated bacteria. Bacteria recovered from the livers of rats treated with 1 or 10 mg/kg body weight of AFB1 exhibited, on average, Lac constitutive mutant frequencies of 49 and 129 X 10~6, respectively (Table I ). These frequencies represent 2.5-and 6.5-fold increases over the spontaneous level. Bacteria recovered from control animals gave 15% of dominant mutations in the lacl gene, which increased to 22 and 31% after AFB1 treatment. Increments of 3.7-and 13.3-fold were thus noted for lacl~d mutants, at survival rates of 45 and 30% for the 1 and 10 mg/kg doses, respectively.
A total of 149 lacl~d mutants from the in vitro treatments, and of 132 from the HMA at the highest dose of 10 mg/kg body weight, were characterized by DNA sequencing (Table  II) . For both mutagenic treatments, all mutants analysed were the result of a single base change, the majority (>90%) were base substitutions and the remainder frameshift mutations. Substitutions occurred primarily at G:C base pairs (>75%), as expected from the fact that activated AFB1 reacts primarily with guanine residues (4, 23) . The assignment of the base from which mutations at G:C base pairs arise is based on the putative predominant role of guanine adducts in AFB1 mutagenesis. Among substitutions, GOTA transversions represented the main mutational change (>45%), but all other possible base substitutions were also observed. Frameshift mutations were furthermore discovered in both mutation spectra.
The mutational distribution for AFBl-induced substitutions is presented in Tables III (at G:C bp) and IV (at A:T bp), and that for frameshift mutations in Table V . The in vitro S9 and the in vivo HMA mutation spectra were not statistically different, according to a computer program for comparison of mutational spectra (24) . The probability that the two input spectra are the same was 0.48, 0.58, 0.52 and 0.30 for comparisons of all mutations, all substitutions, substitutions at G:C base pairs or GOTA transversions, respectively. A siteby-site comparison of all mutation events in both spectra revealed also no statistically significant differences in the rate of recovery (Fisher exact test for differences in proportions).
AFBl-induced substitutions at G:C base pairs were not randomly distributed. Thus, mutations were recovered at 38 out of the 52 available sites for substitutions at G:C, whereas, with random distribution, we would expect only one site not to be included in a collection of this size. Furthermore, assuming Poisson distribution and pooling the data from both 2000 mutation spectra, it can be calculated that sites with at least 12 mutations/site are real hot spots (P < 0.001). Hence, positions 86 (5'-CCG_TTT-3'), 92 (5'-CGCGGG-3'), 93 (5'-CCCGCG3') and 198 (5'-GCCCGCC3') are considered hot spots, accumulating these sites the 7, 13, 10 and 8% of substitutions at G:C bp (total 211), and the 11, 20, 7 and 13% of GOTA transversions (total 128). Two (positions 92 and 93) of the four hotspots had mutations other than GOTA transversions. The hotspot DNA sequences suggest that guanines that are adjacent to, at least, one 5'-C base and to a 3'-G or 3'-C base are more likely to mutate. By chi-square analysis, these influences of the 5' and 3' flanking bases on mutations at G:C base pairs were further demonstrated (calculations not shown).
There are eight G:C sites in the /V-terminal region of the lacl gene at which all three base substitutions can be monitored (25) . As shown in Table VI , the relative proportions of various base substitutions found at these sites agree well with that observed for the complete genetic target. Additionally, more than one type of base substitution was recovered at 12 G:C sites. Mutations at these 12 sites accounted for 53% (111/211) of G:C targeted substitutions.
Discussion
This paper reports the results of sequencing 281 AFB1 -induced lacl~d mutations isolated in an excision repair-defective strain of E.coli which carry in addition the plasmid pKMlOl. This plasmid contains the mucAB genes that are believed to facilitate progression of the replication fork past sites of DNA damage (26) . All events characterized in this study were point mutations with a clear majority (267/281) of base substitutions. Frameshift mutations were also detected though, in agreement with data available in the literature, AFBl-induced frameshifts were rare, occurring in roughly <10% of total forward mutations being analysed (10-14). Seventy-nine per cent (211/267) of all substitutions occurred at G:C sites, in agreement with the idea that metabolically activated AFB 1 reacts primarily with guanine residues to form predominantly AFB 1 -N7-Gua adducts (4, 23) . Likewise, most AFB1 frameshifts occurred within or in the vicinity of G:C runs, where strand slippage events are promoted (10, 22) .
GOTA transversions were the most frequent base substitu-tion induced by AFB1 at G:C sites; however, significant numbers of GOAT and GC>CG changes were also observed. This mutational spectrum exhibits considerable complexity, with more than one type of mutation occurring at 12 out of the 38 G:C targeted substitutions. Incorporation of different bases opposite a single type of non-instructive lesion during error-prone DNA synthesis might explain the results. Kunkel (27) has monitored the mutational specificity of non-instructional lesions derived from depurination and has shown that the distribution of bases incorporated opposite apurinic sites resulting from the loss of guanine is: A, 56%; T, 29%; and G, 15%. The distribution found in this study for the corresponding events following AFB1 treatment was remarkably similar: A, 60%; T, 22%; and G, 18%. The AFB1-N7-Gua primary adduct could thus result mutagenically through an apurinic site intermediate or, alternatively, dATP may be the preferred substrate whenever base hydrogen bonding is not possible, regardless of the actual lesion.
The specificity of substitutions in the present study differs from two previous reports of AFB1 mutagenesis in Escherichia coli. In one, 89% of analysed mutations were GC>TA transversions (15) . That study, however, was restricted to the 70 sites that could be identified by screening amber and ochre nonsense mutations in the entire lad gene. Other more recent work, using DNA sequence data from the lacZ a-complementing gene sequence in bacteriophage M13 (10), yielded results significantly different from both the early study and the results reported here. The frequency (46% of all point mutations) of GC>TA transversion was very similar to ours, but significantly fewer (4%) GC>CG transversions and significantly more (38%) GOAT transitions were detected. The disagreement with the study by Sambamurti et al. (10) might be due to dissimilarities in the mechanisms of mutagenesis between the synthetic model compound (AFBl-2,3-dichloride) and the reactive metabolite (AFB 1-8,9-epoxide), presumably generated in our study after metabolic activation of the parent compound. Differences due to other factors like the nature and number of available sites within the two genetic targets at which mutations will yield the desired selectable phenotype, cannot be discarded either (28) .
In contrast to the previously commented reports on AFB1 mutagenesis in Escherichia coli, our results show similarities with the mutagenic spectrum induced by AFB 1-DNA lesions in human cells (11) . In that study, GOTA transversions represented the predominant mutational change, occurring in slightly over half of all cases. Other major mutations being evenly divided between GOCG transversions and GOAT transitions (around 15% each type). The most striking difference is the relatively large number (around 20%) of substitutions at A:T sites found in our study and its low number (4%) in the human cells. The frequency of these mutations, that could result from infrequent adenine depurinations, rare premutational lesions or minor untargeted mutations, might be enhanced in the excision repair-defective and error prone genetic background of the bacteria in this study.
Several investigators have demonstrated that AFB 1-8,9-oxide does not react randomly with DNA in vitro (23, 29, 30) . The reactivity of a particular guanine is markedly affected by the 5' and 3' flanking bases, and empirical rules have been derived to predict aflatoxin binding to a G based on its nearest neighbours (23) . In this study G:C targeted mutations occurred less frequently at sites flanked (5' and 3') by an A or T base than at sites flanked (5', 3' or both) by a G or C base, in agreement with the idea that single guanine residues flanked by A:T base pairs are poor targets for AFB 1 damage; likewise, hot spot sites were at sequences of high reactivity (5'-COT-S', 5'-CGG-3' and 5'-CGC-3'). Nevertheless, since other equally reactive sequences like 5'-GGG-3' or 5'-GGT-3' were poorly mutated in this study, other factors have to determine the mutability of a particular gene sequence, in addition to the chemical properties of the ultimate mutagen. Among them, local DNA conformation and repairability are recognized to play a role.
Similar types of mutations with similar site specificity were obtained with AFB 1 activated in vivo by means of a rat hostmediated assay or in vitro by a commercially prepared S9 microsomal fraction. These results indicate the ability of the in vitro S9 fraction to mimic the in vivo metabolism, suggesting that the same active metabolite, presumably AFB 1-8,9-epoxide, is responsible for generating a similar pattern of DNA damage in both cases as reflected in the similarity of mutational spectra. A previous study indicated that both the S9 assay and the host-mediated assay gave different mutational specificities for the tobacco-specific carcinogen, 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone (31) . However, the conclusions of such a study were limited, in part, because the in vivo assay was carried out in mice (the species commonly used in the hostmediated assay), while the S9 system used a liver homogenate of rats. The selection of animal species for premutagen biotransformation may be critical since species differences in the activity of many enzymes associated with xenobiotic metabolism are pronounced; e.g. in contrast to the rat, the mouse is relatively resistant to the toxic and carcinogenic effects of AFB1. Detoxification catalysed by glutathione S-transferase is considered the critical determinant of species susceptibility to the harmful effects of AFB1 (3).
